Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
The origin of Elon Musk's feud with Bill Gates, according to Musk's new biography
Three Adani Firms Lose Endorsement of UN-Backed Climate Group
Meta reveals new ‘Voicebox’ AI that is too risky to release
Google Calendar Can Now Tell Coworkers the Exact Times You'll Be in the Office
EU opens investigation into X’s handling of disinformation over Hamas attack on Israel
Boomi Appoints Megan Barbier as Chief Human Resources Officer
South Africa Seeks Water Investment With New Procurement Office
The World Is Focusing on the Wrong Climate Scoreboard